bioRxivCancer Biology
An Isogenic Cell Line Panel for Sequence-based Screening of Targeted Anti-cancer Drugs
A. L. Cook, N. Wyhs, S. B. Sur, B. Ptak, M. Popoli, L. Dobbyn, T. Papadopoulos, C. Bettegowda, N. Papadopoulos, B. Vogelstein, S. Zhou, K. W. Kinzler
Abstract
We describe the creation and characterization of an isogenic cell line panel representing common cancer pathways, with multiple features optimized for high-throughput screening. More than 1,800 cell lines from three normal human cells were generated using CRISPR-technologies. Surprisingly, we discovered most of these lines did not result in complete gene inactivation, despite integration of sgRNA at the desired genomic site. However, a subset of the lines harbored true, biallelic disruptions of the targeted tumor suppressor gene, yielding a final panel of 100 well-characterize lines covering 19 pathways frequently subject to loss of function in cancers. This panel included genetic markers optimized for sequence-based ratiometric assays for drug-based screening assays. To illustrate the potential utility of this panel, we developed a multiplexed high-throughput screen that identified Wee1 inhibitor MK-1775 as a selective growth inhibitor of cells with inactivation of TP53. These cell lines and screening approach should prove useful for researchers studying a variety of cellular and biochemical phenomena.
- organism: human
- assay: CRISPR screen
- research focus: drug response / drug discovery
- approach: genetic perturbation / CRISPR
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Genetic screens in isogenic mammalian cell lines without single cell cloning
Peter C. DeWeirdt, Annabel K. Sangree, … John G. Doench·Nature CommunicationsPeer-reviewed·Feb 6, 2020
- Intercellular CRISPR Screens Enhance the Discovery of Cancer Immunotherapy Targets
- Drug mechanism-of-action discovery through the integration of pharmacological and CRISPR screens
Emanuel Gonçalves, Aldo Segura‐Cabrera, … Mathew J. Garnett·Molecular Systems BiologyPeer-reviewed·Jul 1, 2020
- Prioritisation of oncology therapeutic targets using CRISPR-Cas9 screening
F. M. Behan, F. Iorio, … G. J. Mathew·bioRxiv·Dec 20, 2018
- VHL Synthetic Lethality Signatures Uncovered by Genotype-specific CRISPR-Cas9 Screens
N. Sun, S. Petiwala, … N. Chung·bioRxiv·Mar 26, 2019
- Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal
J. M. Krill-Burger, J. M. Dempster, … A. Tsherniak·bioRxiv·Mar 2, 2022